Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Avidia closes $28.5mm Series B round

Executive Summary

Avidia Inc. (protein therapeutics) raised $28.5mm through the sale of Series B preferred shares. Morgenthaler Ventures led the round and was joined by other new investors TPG Ventures, MedImmune Ventures, and Amgen Ventures, and returning backers Alloy Ventures, Maxygen (which created Avida in 2003 as a spin-off), Avidia scientific founder Willem Stemmer, and other individuals.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies